Evidence map›Paper›PMID 41679332›Full record

ArticleThe Journal of infectious diseases2026

Efficient Sensing of a 4-Segmented Rift Valley Fever Virus Vaccine Candidate by Human Monocytes.

Niranjana Nair, Julia Friese, Paul J Wichgers Schreur, Albert D M E Osterhaus, Guus F Rimmelzwaan, Chittappen Kandiyil Prajeeth

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Niranjana NairResearch Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover  Foundation, Germany.ORCID 0000-0003-3374-3321
Julia FrieseResearch Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover  Foundation, Germany.
Paul J Wichgers SchreurDepartment of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, Lelystad, Netherlands.ORCID 0000-0001-9790-2438
Albert D M E OsterhausResearch Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover  Foundation, Germany.ORCID 0000-0002-6074-1172
Guus F RimmelzwaanResearch Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover  Foundation, Germany.
Chittappen Kandiyil PrajeethResearch Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover  Foundation, Germany.ORCID 0000-0002-6631-2096

Funding

Deutsche Forschungsgemeinschaft 398066876/GRK 2485/2University of Veterinary Medicine Hannover Foundation
6 · The paper itself

Abstract

The live-attenuated RVFV-4s vaccine against Rift Valley fever has demonstrated safety and efficacy across multiple animal models and in a phase 1 clinical trial. In this study, we examined its impact on innate immune responses and found that RVFV-4s enhances the expression of costimulatory molecules critical for T-cell activation, while triggering proinflammatory responses in primary human monocytes.

Indexed as

MonocytesRift Valley FeverRift Valley fever virusViral VaccinesHumansImmunity, InnateLymphocyte ActivationT-LymphocytesVaccines, AttenuatedVaccines, AttenuatedViral VaccinesM1 macrophagemonocyteproinflammatory responseRVFV-4sT-cell activation

Identifiers

PMID41679332
PMCPMC13431889

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.